Comparative table of low molecular weight heparins
Specialist Pharmacy Service
In light of current shortage of enoxaparin injection (all strengths), this table of the licensed low molecular weight heparins has been drawn up to compare/contrast key prescribing parameters.
The Lancet Neurology
This Series paper explores current understanding of clinical course and underlying mechanisms of coagulopathy in traumatic brain injury. Management strategies are reviewed, including traditional use of blood products and more novel approaches, as well as thrombosis prophylaxis.
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
New England Journal of Medicine
Final analysis from RE-VERSE AD (n=510) reported that the primary endpoint, reversal of the anticoagulant effect of dabigatran within four hours as measured by diluted thrombin time and ecarin clotting time, was observed in 100% of patients (95% CI, 100-100).
Revised SPC: Xarelto (rivaroxaban) film coated tablets (all strengths)
electronic Medicines Compendium
Serious skin reactions, including Stevens-Johnson syndrome/Toxic Epidermal Necrolysis, have been reported. The highest risk appears to be early in the course of therapy. Treatment should be discontinued at the first appearance of a severe skin rash.
British Journal of Clinical Pharmacology
This article gives an overview of the biophysical, pharmacokinetic and pharmacodynamic properties of anticoagulants currently available for the initial management of PE including low molecular weight heparins and direct oral anticoagulants.
The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:
http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services
